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Abstract: Canine progressive retinal atrophies (PRA) are genetically heterogeneous diseases
characterized by retinal degeneration and subsequent blindness. PRAs are untreatable and affect
multiple dog breeds, significantly impacting welfare. Three out of seven Giant Schnauzer (GS)
littermates presented with PRA around four years of age. We sought to identify the causal variant
to improve our understanding of the aetiology of this form of PRA and to enable development
of a DNA test. Whole genome sequencing of two PRA-affected full-siblings and both unaffected
parents was performed. Variants were filtered based on those segregating appropriately for an
autosomal recessive disorder and predicted to be deleterious. Successive filtering against 568 canine
genomes identified a single nucleotide variant in the gene encoding NECAP endocytosis associated 1
(NECAP1): c.544G>A (p.Gly182Arg). Five thousand one hundred and thirty canids of 175 breeds,
10 cross-breeds and 3 wolves were genotyped for c.544G>A. Only the three PRA-affected GS were
homozygous (allele frequency in GS, excluding proband family = 0.015). In addition, we identified
heterozygotes belonging to Spitz and Dachshund varieties, demonstrating c.544G>A segregates in
other breeds of German origin. This study, in parallel with the known retinal expression and role of
NECAP1 in clathrin mediated endocytosis (CME) in synapses, presents NECAP1 as a novel candidate
gene for retinal degeneration in dogs and other species.
Keywords: canine; dog; progressive retinal atrophy; PRA; retinal degeneration
1. Introduction
Inherited retinal degenerations are a group of heterogeneous diseases characterized by loss of rod
and/or cone photoreceptors eventually leading to vision loss. In humans, retinitis pigmentosa (RP) is
the most common form, affecting 1 in 4000 worldwide [1] before middle age. Typically, night blindness
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is the first sign of RP caused by an initial depletion in rod photoreceptors followed by cones leading to
a gradual reduction in vision.
Canine retinal degenerations present similarly to human forms of the disease and can be broadly
categorized as stationary or progressive retinal disorders [2]. Collectively, these progressive forms are
termed canine progressive retinal atrophies (PRA), with differences discussed in depth by others [3,4].
Variability in age of onset, aetiology, and rate of progression is observed in canine PRA, yet most forms
share a similar ophthalmoscopic appearance. Fundus changes observed are bilateral and include
tapetal hyper-reflectivity caused by retinal thinning, retinal blood vessel attenuation, and, in advanced
stages, optic nerve head atrophy.
Canine retinal degeneration affects multiple breeds and is clinically and genetically heterogeneous
across and within breeds. To date, 32 mutations have been associated with stationary and progressive
forms across over 100 breeds. Twenty-five of these are associated specifically with PRA [5–27].
Although the majority of these are single gene autosomal recessive disorders, dominant [8] and
X-linked forms [9,23] have been exemplified, as well as one age-modifying mutation [24]. Whilst
there are PRA mutations that are shared by multiple breeds [11,19,28], many are private to a single
breed [6,7,17,21,25] or are found in breeds sharing similar ancestral backgrounds, e.g., rod-cone
degeneration-4 (RCD4) in Gordon and Irish Setters [19]. This is largely due to breed barriers and the
existence of isolated populations within purebred dog breeds, where phenotypic variation within
breeds is limited and dogs from the same breed are genetically more similar compared to those of
different breeds [29]. In contrast, there have been PRA mutations found across seemingly unrelated
breeds, including the RCD4 mutation present in Tibetan Terriers and the PRCD mutation found across
many diverse breeds [11].
Currently, there is no treatment or cure for PRA; therefore, the use of genetic technologies to
identify PRA-causing variants is crucial to facilitate diagnostic DNA test development for dog breeders
and owners, with the aim to reduce the frequency of PRA-associated variants in dog breeds. Clinical
eye screening schemes, including the British Veterinary Association/ Kennel Club/ International
Sheep Dog Society (BVA/KC/ISDS) eye scheme in the UK (https://www.bva.co.uk/Canine-Health-
Schemes/Eye-scheme/) and the ECVO (European College of Veterinary Ophthalmologists) Eye scheme
(https://www.ecvo.org/hereditary-eye-diseases/eye-scheme), enable dog breeders and owners to screen
for a list of inherited eye conditions in certain breeds to reduce the prevalence of certain eye diseases.
Genetic testing complements clinical eye screening methods with the advantage of detecting known
PRA mutations before breeding age or before clinical signs present. Similarities in eye size and clinical
phenotypes of eye conditions in both dogs and humans presents the dog as an excellent model for
studying inherited eye diseases in humans [30–32]. Studies of canine PRA offer a source for novel
candidate gene identification and target gene discovery for retinal disease across species, including
humans where a large proportion of patients still have an unknown molecular diagnosis.
Here, we describe a novel form of PRA implicating the gene encoding NECAP endocytosis
associated 1 (NECAP1) in the Giant Schnauzer (GS) dog, a breed which originated in Germany in the
17th century. The GS is the largest of three sizes: Giant, Standard, and Miniature. Although the precise
origins are unclear, it is thought the breed was developed using the Standard Schnauzer, Rottweiler,
Great Dane, German Shepherd, and perhaps Bouvier De Flandres, although originally the GS was
considered a rough-coated version of the German pinscher breeds [33]. The breed was imported
to North America in the 1920s and 1930s, yet after the Second World War, the number of GS dogs
diminished. Breeding stocks were introduced to the UK in the 1960s. Today, the three breed sizes do not
interbreed and are recognized as distinct breeds. Currently, the GS is recognized by the BVA/KC/ISDS
eye scheme as being affected with inherited cataracts but not PRA. To our knowledge, these affected
GS dogs are the first PRA cases in the UK, and this is also the first instance that NECAP1 has been
implicated in retinal degeneration in any species. Although the small number of cases suggests this
is a newly emerging form of PRA in the breed, identification of the genetic cause will enable further
screening in the breed to confirm or exclude this hypothesis and improve our understanding of the
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aetiology of this form of PRA. The availability of a DNA test based on this variant will also prevent
this form of PRA from becoming widespread in the GS population.
2. Materials and Methods
2.1. PRA Diagnosis and Sample Collection
PRA was initially diagnosed in a four-year-old GS dog by a board-certified veterinary
ophthalmologist also qualified as a BVA/KC/ISDS eye scheme panelist (https://www.bva.co.uk/
Canine-Health-Schemes/Eye-scheme/) and a diplomate of the European College of Veterinary
Ophthalmologists at the Animal Health Trust. Ophthalmoscopic examination detected widespread
tapetal hyper-reflectivity and retinal vascular attenuation, consistent with PRA (Figure 1). Follow-up
examination of littermates detected a total of three of the seven dogs to be affected by PRA by
board-certified veterinary ophthalmologists. The sire and dam were clinically unaffected at 8 and
11 years of age, respectively, and, therefore, considered likely to be obligate carriers of an autosomal
recessive mutation causing PRA in this family. Neurological examination was performed in all dogs
and revealed no abnormalities. A review of the medical records of each dog showed no history of
neurological disease in any dog.
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Figure 1. Fundus images captured showing (A) unaffected Giant Schnauzer (GS) dam at 11 years;
(B) progressive retinal atrophies (PRA)-affected GS dog at 5 years of age. Observations of PRA cases
include bilateral tapetal hyperrelectivity and retinal vascular attenuation.
Collection of DNA samples from animals using buccal mucosal swabs was approved by the
AHT Ethics Committee (ref no. 24-2018E). PRA-affected dogs (cases) were defined as presenting
with clinical signs consistent with PRA and unaffected dogs (controls) as dogs clear of inherited eye
diseases upon ophthalmoscopic examination. DNA was extracted from buccal mucosal swabs using the
QIAamp DNA Blood Mini or Midi Kits (Qiagen, Manchester, UK). DNA concentration and purity were
determined using the NanoDrop 1000 spectrophotometer (Thermo Fisher Scientific, Loughborough,
UK) and/or the Qubit Fluorometer with the Qubit dsDNA broad range (BR) Assay Kit (Invitrogen,
Loughborough, UK). Where possible, DNA samples with concentrations <10 ng/µL were concentrated
using MultiScreen-PCR96 filter plates (Millipore, Watford, UK) or Microcon −30 kDa centrifugal filter
units with ultracel-30 membrane (Millipore, Watford, UK). For the Finnish cohort, eye examinations
were conducted by veterinary ophthalmologists board-certified by the European College of veterinary
ophthalmologists; 3 mL EDTA-blood was collected under the permission of animal ethical committee of
County Administrative Board of Southern Finland (ESAVI/343/04.10.07/2016) and DNA was extracted
from white blood cells using a semi-automated Chemigen extraction robot (PerkinElmer Cheagen
Technologie GmbH, Baeswieler, Germany) according to manufacturer’s instructions. Breed-specific
allele frequencies for the NECAP1 variant were determined using cohorts of dogs genotyped by the
Animal Health Trust, UK; University of Bern, Switzerland; and University of Helsinki, Finland. A
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sample cohort genotyped by Mars Veterinary, UK, provided further screening of the NECAP1 variant
across multiple dog breeds, including mixed breed dogs and dogs of unknown breeds.
2.2. Exclusion of Known Retinal Mutations
Twenty-six previously published retinal mutations (Supplementary Table S1) were screened for
using a genotyping-by-sequencing method. Primer pairs were designed spanning each mutation to
amplify products between 110–130 bp in size. Fifteen primer pairs were pooled and a multiplex PCR
was performed. Multiplex PCR and thermal cycling conditions are listed in Supplementary Tables S2
and S3. Purification was carried out after each thermal cycling reaction using AMPure XP beads
(Beckman Coulter, High Wycombe, UK), according to manufacturer’s instructions, and using 1:1.75
ratio of beads to DNA-containing solution. Adaptor ligation was performed followed by amplification
to create sequencing libraries. Five microliters (µL) of each sample library was pooled and quantified
using KAPA library quantification kit, according to manufacturer’s instructions (Kapa Biosystems,
Wilmington, MA, USA). The final library was diluted to 15 picomoles (pM) and loaded into a 150 bp v3
kit cartridge (Illumina, Cambridge, UK) for single ended sequencing on the MiSeq sequencing platform
(Illumina). FASTQ files were aligned to the canine genome assembly CanFam3.1 (Sep.2011. Broad
CanFam3.1/canFam3, Ensembl (www.ensembl.org; Dog release 89) [34]) using BWA, producing BAM
files. BAM files were visualized in Integrative Genomics Viewer (IGV) [35,36]. Large insertions or
deletions or variants within repetitive regions, applicable for a total of eight mutations, were genotyped
using PCR amplification, followed by amplified fragment analysis or visualization on an agarose gel
using gel electrophoresis.
2.3. Whole Genome Sequencing
The four GS samples selected for whole genome sequencing (WGS) (2 PRA cases and both
unaffected parents; study accession number PRJEB32096) were normalized to 25 nanograms per µL
(ng/µL), and 1000 ng was sent for sequencing, outsourced to Edinburgh Genomics, UK. Illumina
sequencing of a TruSeq Nano library on a HiSeq X sequencing platform generated a dataset of
approximately 30× coverage of the dog genome. Reads were aligned to the canine reference genome
(CanFam3.1) using BWA-mem, variant calls were made using GATK (HaplotypeCaller) and base
quality score recalibration, and indel realignment and duplicate removal were performed [37]. Single
nucleotide polymorphism (SNP)and small insertion/deletion (INDEL) discovery was performed
using standard hard filtering parameters or variant quality score recalibration according to GATK
Best Practices recommendations [38,39]. Sequencing reads and variants were visualized in IGV.
Genomic Variant Call Format (VCF) files from 116 canine WGS were combined by HaplotypeCaller
into a multi-sample VCF file. Variant Effect Predictor (VEP) was run on the merged VCF file for
cross-genome analysis.
2.4. Variant Filtering
Variants from WGS data were filtered appropriately for an autosomal recessive mode of inheritance,
i.e., variants were retained if cases were homozygous, parents heterozygous, and controls homozygous
for the alternate allele. An in-house analysis pipeline generated an effect score for each variant,
depending on its predicted effect on the protein sequence and whether it is predicted to be deleterious.
Variant filtering retained variants with a high effect score, including those resulting in premature
start/stop codons, splice site variants, nonsense and missense variants, frameshift variants, and in-frame
deletions. Study co-authors (C.S.M., O.P.F., H.L., T.L.) are members of the Dog Biomedical Variant
Database consortium (DBVDC), which contained 452 WGS at the time of the study; these sequences
were used for additional variant filtering. The Ensembl genome browser (www.ensembl.org; Dog
release 89) [34] and UCSC genome browser (http://genome.ucsc.edu/) were used to obtain canine
genome sequence (Sep.2011. Broad CanFam3.1/canFam3) to interrogate regions. Mutation Analyzer,
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PolyPhen-2, Mutation Taster2, and SIFT (sorting intolerant from tolerant) were used to predict the
impact of amino acid substitutions on the structure and function of proteins [40–43].
2.5. Variant Screening
Primers and allelic discrimination probes were designed using Primer3 [44,45] and obtained
from Integrated DNA Technologies (IDT, Leuven, Belgium) (Supplementary Table S4). Probes were
PrimeTime ZEN double-quenched qPCR probes containing a 5’ fluorophore, 3’ Iowa Black®FQ (IBFQ)
quencher and proprietary, internal ZEN™ quencher. A 5′ HEX™ fluorophore was used to determine
the reference allele and a FAM™ fluorophore to label the alternate allele. Individual PrimeTime assays
were re-suspended in ultrapure water to a 40×mix and combined. Allelic discrimination assays were
carried out using Luna Universal qPCR Master Mix (New England Biolabs, Hertfordshire, UK) on
a StepOnePlus™ Real-Time PCR system (Thermo Fisher Scientific, Loughborough, UK) using the
following cycling conditions: 25 ◦C for 30 s; 95 ◦C for 3 min; 35 cycles of 95 ◦C for 3 s, followed by
60 ◦C for 10 s; and a final post-PCR stage at 25 ◦C for 30 s. Results were analyzed using Applied
Biosystems StepOne Software v2.3. For the Finnish cohort, primers were designed using Primer3
(forward: 5’-TGGTTTCTTTCCCCTACTCCC; reverse: AATGGGTGGTGGAGTGACAT) to amplify
DNA by PCR using the following cycling conditions: initial denaturation at 95 ◦C for 5 min; 37 cycles
denaturing at 95 ◦C for 30 s, annealing at 59 ◦C for 30 s, and elongation at 72 ◦C for 45 s; followed by a
final elongation step at 72 ◦C for 10 min. PCR components are listed in Supplementary Table S5 and
PCR products were sequenced by Sanger sequencing.
2.6. Sanger Sequencing of NECAP1 Variant
To confirm the c.544G>A (p.Gly182Arg) SNV and its segregation in all three GS PRA cases, PCR
followed by Sanger sequencing were performed. Forward (5’–GGCTTCAAGGAAGGACAGACT-3’)
and reverse (5’- GATACGATGATTCCTCAAAGTTAAA-3’) primers were designed using Primer3
to amplify a 350 bp product flanking the candidate variant using the following PCR conditions:
denaturation at 95 ◦C for 5 min; 35 cycles at 95 ◦C for 30 s, 58 ◦C for 30 s, and 72 ◦C for 30 ◦C followed
by a final elongation step at 72 ◦C for 5 min. PCR products were purified on a MultiScreen-PCR96
filter plate (Millipore, Watford, UK) and sequenced using the Sanger method using Bigdye v3.1
chemistry (Life Technologies Ltd., Loughborough, UK) and the following conditions: 96 ◦C for 30 s; 44
cycles at 92 ◦C for 4 s, 55 ◦C for 4 s, and 60 ◦C for 1.5 min. Isopropanol precipitation of sequencing
reaction products removed excess reagents and precipitated DNA was resuspended in 10 µL Hi-Di
Formamide (Applied Biosystems, Loughborough, UK). Sequencing products were separated on an
Applied Biosystems (ABI) 3130xl genetic analyzer and data analyzed using the Staden software package
(http://staden.sourceforge.net/).
2.7. Expression of NECAP1 in Canine Retina, Using RNAseq Data
RNAseq data generated from retinal RNA of a Petit Basset Griffon Vendeen (PBGV) control dog
for a previous unrelated project [46] was used to determine gene expression. Three genes known to be
implicated in retinal degeneration and expressed in retinal tissue (RPGRIP1, RHO, and GNAT1) and
three genes with low/no expression in human retinal tissue (ANXA1, MYH41, MYOT) were selected as
control genes based on RNAseq expression data published in GeneCards [47]. The total number of
reads aligned to each of the six control genes was obtained using BEDTools v2.17.0 “coverage” tool [48]
and compared to that of NECAP1. An average number of reads per exon was calculated for each gene.
2.8. Haplotype Analyses
A total of eight SNVs, four either side of the NECAP1 variant, that were homozygous in the cases
and heterozygous in the parents were selected for genotyping. SNVs were situated up to 573 kilobases
(kb) downstream of the variant and 301 kb upstream. Primers were designed using Primer3 and
products amplified using PCR conditions, purification, and Sanger sequencing, as described above.
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Primers are listed in Supplementary Table S6. SNVs surrounding the variant were genotyped across
two GS PRA cases, both GS parents, one control GS, one heterozygous Giant Spitz, six heterozygous
Miniature Longhaired Dachshunds, and a control Miniature Longhaired Dachshund to determine a
disease-associated haplotype.
2.9. Autozygosity Mapping
Illumina Canine HD array SNP positions were extracted from the four GS WGS data into binary files
using PLINK2 (www.cog-genomics.org/plink/2.0/) [49] and an in-house PERL script. PLINK v1.07 [50]
was used to identify runs of homozygosity (ROH) using sliding windows across the SNP data using the
default values: -homozyg-window-kb 5000 (length in kb of the sliding window); -homozyg-window-snp
50 (minimum number of SNPs that the sliding window requires); -homozyg-window-het 1 (allowing 1
heterozygous SNP in a window to tolerate genotyping errors); -homozyg-window-missing 5 (allowing
up to 5 missing calls in a window); -homozyg-window-threshold 0.05 (proportion of overlapping
windows required as homozygous to define a given SNP in a ROH); -homozyg-snp 100 (sliding window
of 100 SNPs); -homozyg-kb 1000 (sliding window of 1000 kb/ 1 megabase (Mb)); -homozyg-density 50
(minimum density of 1 SNP per 50 kb); and -homozyg-gap 1000 (split a segment into two if the distance
between two SNPs is >1000 kb, i.e., retaining ROH >1 Mb in size). ROH overlapping with one or
both parents were removed leaving those homozygous only in the cases, leaving, by definition, ROH
heterozygous in the parents. Genes within each ROH block were cross-referenced with the RetNet
database [51] and RetNet gene regions were visualized in the GS WGS data for high impact SNVs or
structural variants.
3. Results
3.1. Exclusion of Known Retinal Mutations
Screening for 26 previously published retinal mutations (Supplementary Table S1) revealed all
PRA-affected GS were homozygous for the wildtype allele for all these mutations.
3.2. NECAP1 Variant Identification
Genome sequencing data of two PRA-affected full-siblings were compared with corresponding
data of their unaffected parents and 112 control dogs of various breeds. Variants were filtered by the
predicted effect of each variant on the transcript and protein and then based on those segregating
appropriately for an autosomal recessive disorder. A total of 25,658,899 variants were detected
amongst 116 canine genomes of multiple breeds, including the four GS genomes. Filtering for protein
changing variants reduced this number to 102,716 variants. Five of these high effect variants segregated
appropriately in both cases and parents and were absent from our initial control set of 112 canine
genomes. Additional filtering against genomes in the DBVDC (452 genomes of 94 individual breeds,
eight cross breeds, and three wolves) further reduced this set of five variants down to three. Two
variants were situated within a novel gene, ENSCAFG00000030684, for which no human homologues
exist nor do any annotated genes lie nearby. This left a single candidate missense variant in the gene
NECAP1 encoding NECAP endocytosis associated 1 for which, aside from the two GS parents, only
one additional heterozygous dog (Giant Spitz breed) was identified in the full dataset of 568 genomes
(WGS controls and DBVDC cohort). The c.544G>A (p.Gly182Arg) SNV is in exon 6 of 8 in NECAP1
(chr27:37,468,611) (CanFam 3.1 assembly; Figure 2) and is predicted to cause a glycine to arginine
amino acid substitution. This glycine is highly conserved across 31 mammals, including humans and
mice at this position.
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Figure 2. Whole genome sequencing (WGS) analysis in Integrative Genomics Viewer (IGV) of GS PRA
cases homozygous (A,B) for the c.544G>A (p. ly182Arg) single nucleotide variant (SNV) in exon 6 of 8
of NECAP endocytosis associated 1 (NECAP1), unaffected sire (C) and dam (D) heterozygous for the
variant, and Vizsla control homozygous for the wildtype allele (E).
To assess whether the c.544G>A variant amino acid substitution affects protein function,
bioinformatics tools Mutation Analyzer, PolyPhen-2, utation Taster2, and SIFT were used to
predict the effect of the missense variant. utation nalyzer and PolyPhen-2 predicted the a ino
acid change to be rarely tolerated and probably da aging to the protein, respectively. utation
Taster predicted the amino acid substitution to be disease-causing and SIFT predicted the change to be
deleterious with a SIFT score f 0.03.
3.3. Variant Screening
Sanger sequencing confirmed all three PRA-affected GS dogs were homozygous for the mutant
allele (A/A), both obligate carrier parents were heterozygous (G/A) and the remaining four unaffected
littermates were either heterozygous or homozygous for the wildtype allele (G/G) (Figure 3).
To investigate whether the variant is common in the breed, additional GS dogs were genotyped for
the c.544G>A variant. Six additional GS heterozygotes were initially found. Screening an additional
427 dogs of 122 breeds, including 65 Miniature Schnauzers, identified one Miniature Longhaired
Dachshund that was heterozygous for the c.544G>A variant.
3.4. Population Screening
The presence of the NECAP1 variant in additional breeds led to screening of Miniature Longhaired
Dachshunds and Spitz varieties. In total, the candidate variant was genotyped in 5130 dogs of 175
breeds, 10 cross breed dogs, and 3 wolves, including a total of 322 GS dogs, were genotyped for
c.544G>A (p.Gly182Arg). Only the three PRA-affected GSs were homozygous for the variant and
18 heterozygotes were identified, nine of which were closely related (up to three generations) to the
probands, and nine were either known to be not closely related to the affected dogs based on pedigree
information, or deemed unknown due to lack of pedigree information. Allele frequency in GS dogs,
excluding closely related dogs, was 0.015. Genotyping cohorts of additional breeds of German origin,
including Spitz and Dachshund varieties, identified heterozygotes of the variant. Genotyping data
were compiled and allele frequencies determined (Table 1). Four PRA affected dogs (two Miniature
(Klein) Spitz and two Pomeranian) were included in the testing cohorts: these were homozygous
wildtype suggesting that in these two breeds there are multiple forms of PRA. Out of the total 5130
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canids genotyped for the NECAP1 variant, the only dogs homozygous for the variant were the three
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Figure 3. Sanger sequencing traces showing the c.544G>A SNV in NECAP1 in three PRA affected GS
DNA (A–C); the heterozygous unaffected sire (D) and dam (E); a homozygous wildtype unaffected
sibling (F), and a heterozygous unaffected sibling (G).
Table 1. Total allele frequency of NECAP1 single nucleotide variant (SNV) in multiple breeds of dog.
Breed NECAP1+/+ NECAP1−/+ NECAP1−/− Allele Frequency
Giant Schnauzer (GS) 301 18 3 0.037
GS * 300 9 0 0.015
Giant Spitz 106 7 0 0.031
Medium Spitz 146 5 0 0.017
Miniature Spitz 106 8 0 0.035
Pomeranian Spitz 56 3 0 0.025
Miniature Lo ghaired Dachshund 157 8 0 0.024
175 other breeds or unknown breeds 4206 0 0
* excluding third generation relatives to probands from known pedigree information.
One of the study cohorts (Mars Veteri ary, UK) consisted of a combination of unconfirmed breeds
and mixed breed dogs (n = 3162) in which 21 additional heterozygotes were identifie . Heterozygot s
of the followi g purebr ds were ide tified: Miniat re L nghair d Dachshund (n = 2), Sh th ired
Dachshund ( = 1), Miniature Spitz (n = 2), and GS (n = 1); 13 mixed breed dogs were identified
for which breed compositions could be estimated (Suppleme tary Table S7). Breed type could not
b stimated for two heterozygotes in this cohort. As this cohort included various mixed b eed or
unknown breeds of dogs, these were excluded from the breed specific allele frequency calculations.
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3.5. NECAP1 Is Expressed in Canine Retina
A qualitative measure of expression was observed by extracting the total number of reads per
exon from PBGV retinal RNAseq data and calculating a mean number of reads per exon for each gene
(Table 2). A total of 749 reads aligned over all eight exons of NECAP1, with 288 reads aligned specifically
over exon six (Figure 4), providing evidence that NECAP1 is expressed in canine retinal tissue.
Table 2. The total number of exonic reads in three genes expressed in human retinal tissue and three
genes with low/no expression in human retina was extracted and the mean number of reads per exon
calculated. Comparison of these six control genes and the values generated for NECAP1 using canine
RNAseq data showed reads aligning to NECAP1 providing evidence of gene expression in the Petit
Basset Griffon Vendeen (PBGV) control canine retina.
Gene CanFam3.1 ChromosomalCoordinates
Total Number of
Exonic Reads
Mean Number of
Reads Per Exon
RPGRIP1 15: 18316887-18387548 1458 58
RHO 20: 5632150-5637404 461640 92328
GNAT1 20: 39129469-39133156 118800 13200
ANXA1 1: 84744444-84763121 120 9
MYH41 5: 34748657-34767076 3 0
MYOT 11: 25591798-25592328 40 4
NECAP1 27: 37460607-37506942 749 94
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to the CanFam3.1 c nine ge ome sh w reads mapping to NECAP1.
3.6. Haplotype Analyses
To establish whether the NECAP1 variant is due to recurrent independent mutation events or
inherited identically by descent, SNVs flanking the variant were genotyped in the two GS PRA cases,
both GS parents, one control GS, one heterozygous Giant Spitz, six heterozygous Miniature Longhaired
Dachshunds, and a control Miniature Longhaired Dachshund. SNVs present as homozygous for the
alternate allele in the GS PRA cases and heterozygous in the obligate carrier parents were determined.
Shorter haplotypes were revealed in the Giant Spitz and Miniature Longhaired Dachshund, with
the shortest in the Dachshund, compared to that of the GS, suggesting the shared region may be an
ancestral and ancient haplotype (Figure S1).
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3.7. Autozygosity Mapping
After filtering and quality control, 106,298 SNPs were tested through PLINK and identified thirteen
ROH that were over 1 Mb in size and shared exclusively by both GS PRA cases (Table 3, Figure 5).
Table 3. PLINK analysis identified 13 runs of homozygosity (ROH) exceeding 1 Mb in size present in
both PRA affected GS dogs. The NECAP1 single nucleotide variant (SNV) lies within the 9.03 Mb ROH
identified on chromosome 27.
CanFam3.1 Chromosomal Coordinates Size (Mb)
1:29970719-33682751 3.71
6:33954067-39111638 5.16
8:59486837-65640116 6.15
10:64657382-69250914 4.59
13:58887427-60841228 1.95
21:12842407-19235893 6.39
23:54039-17493091 17.44
25:23239981-26009032 2.77
27:36722004-45753342 9.03
28:13922125-15662789 1.74
29:38572915-41054487 2.48
30:1366-26126946 26.13
36:17518975-21096460 3.58Genes 2019, 10, x 11 of 17 
 
 
Figure 5. Chromosomal positions of runs of homozygosity (ROH) greater than 1 Mb in size (blue), on 
canine autosomes in the two GS PRA cases, as obtained through PLINK analysis. The red block 
indicates the 9.03 Mb ROH on chromosome 27 in which the NECAP1 variant lies. 
Eight ROH harbored at least one RetNet gene; however, no structural variants nor 
protein-changing variants were detected upon visualization of WGS data from both PRA-affected 
cases and unaffected parents. The NECAP1 variant lies within a 9.03 Mb ROH on canine 
chromosome 27 (CANFA27). 
4. Discussion 
In this study, we presented novel findings associated with, to our knowledge, a novel form of 
PRA in the GS. The use of WGS technologies has thrived in the past five years and is being 
increasingly used in genetic studies to identify causative mutations associated with inherited 
diseases across species. This has led to success in identifying mutations in canine inherited diseases 
using a very small number of cases and is a cost-effective approach when genome-wide association 
study (GWAS) or other positional approaches are unattainable with small sample numbers. Through 
WGS a quartet of GS dogs (two full-siblings and both parents), we have identified a novel candidate 
missense variant in NECAP1; this gene has not formerly been implicated in retinal degenerations in any 
species. By sequencing two cases and their unaffected parents, comparing the WGS of this quartet with 
those of a large bank of dogs of other breeds, and assuming an autosomal mode of inheritance, our 
ability to filter candidate variants was considerable. 
The NECAP1 gene on CANFA27 is comprised of eight exons spanning 46 kb. NECAP1 encodes 
NECAP endocytosis associated 1, also termed adaptin ear binding coat associated protein 1, a 
subunit of the adaptor protein-2 (AP-2) complex involved with clathrin mediated endocytosis (CME) 
in synapses [52]: a vesicular transport event that primarily initiates the entry of clathrin-coated 
vesicles (CCVs) into cells. The process involves nutrient uptake, signalling and recycling of 
receptors, as well as playing a role in synaptic vesicle reformation [53,54] which is crucial for normal 
cell function. AP-2 is central to CME, during which a subunit of AP-2 binds to the clathrin coat 
Figure 5. Chromosomal positions of runs of homozygosity (ROH) greater than 1 Mb in size (blue),
on canine autosomes in the two GS PRA cases, as obtained through PLINK analysis. The red block
indicates the 9.03 Mb ROH on chromosome 27 in which the NECAP1 variant lies.
Eight ROH harbored at least one RetNet gene; however, no structural variants nor protein-changing
variants were detected upon visualization of WGS data from both PRA-affected cases and unaffected
parents. The NECAP1 variant lies within a 9.03 Mb ROH on canine chromosome 27 (CANFA27).
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4. Discussion
In this study, we presented novel findings associated with, to our knowledge, a novel form of PRA
in the GS. The use of WGS technologies has thrived in the past five years and is being increasingly used
in genetic studies to identify causative mutations associated with inherited diseases across species. This
has led to success in identifying mutations in canine inherited diseases using a very small number of
cases and is a cost-effective approach when genome-wide association study (GWAS) or other positional
approaches are unattainable with small sample numbers. Through WGS a quartet of GS dogs (two
full-siblings and both parents), we have identified a novel candidate missense variant in NECAP1; this
gene has not formerly been implicated in retinal degenerations in any species. By sequencing two
cases and their unaffected parents, comparing the WGS of this quartet with those of a large bank of
dogs of other breeds, and assuming an autosomal mode of inheritance, our ability to filter candidate
variants was considerable.
The NECAP1 gene on CANFA27 is comprised of eight exons spanning 46 kb. NECAP1 encodes
NECAP endocytosis associated 1, also termed adaptin ear binding coat associated protein 1, a subunit
of the adaptor protein-2 (AP-2) complex involved with clathrin mediated endocytosis (CME) in
synapses [52]: a vesicular transport event that primarily initiates the entry of clathrin-coated vesicles
(CCVs) into cells. The process involves nutrient uptake, signalling and recycling of receptors, as well
as playing a role in synaptic vesicle reformation [53,54] which is crucial for normal cell function. AP-2
is central to CME, during which a subunit of AP-2 binds to the clathrin coat membrane and traps
various transmembrane proteins, including cargo receptors, to enrich CCVs [52]. CME is present, albeit
playing a minor role, in retinal ribbon synapses in photoreceptors and bipolar cells of the retina.
A nonsense mutation in NECAP1 has previously been associated with a recessive early infantile
epileptic encephalopathy (EIEE) in humans [55]. Clinical signs of EIEE include severe intractable
seizures from early infancy with a progressive change in frequency and intensity. No retinal
abnormalities were detected in the study by Alazami et al. [55] following electroretinogram of
patients homozygous for the nonsense variant. However, patients with other forms of EIEE have been
reported to show signs of retinal degeneration in addition to typical EIEE clinical signs [56,57]. One
study described an infant that was homozygous for a missense variant in the ARV1 gene that presented
with a form of autosomal recessive EIEE. Ophthalmoscopic evaluation revealed minimal pupillary
response to light leading to a diagnosis of retinal degeneration. The patient died at one year of age [56].
A second study identified a novel single base pair deletion in GNB5 causing a syndromic form of EIEE.
Patients presented with signs of EIEE, as well as retinal degeneration, cardiac abnormalities, severe
neurological developmental delay, and premature sudden death [57]. Although these three discussed
forms of EIEE are caused by mutations in different genes, it can be speculated that the patient that was
homozygous for the NECAP1 variant [55] that died around seven years of age, may not have survived
long enough to develop retinal changes. Arguably, patients reported by in Palmer et al. [56] and
Turkdogan et al. [57] may have had both EIEE and retinal degeneration as a result of genetically distinct
diseases. Although no MRI scans nor neurological examinations were carried out on the GS dogs in
our study, no obvious neurological abnormalities were noted by the veterinary ophthalmologist(s) or
by their owner. It can also be hypothesized that the predicted premature truncation of the NECAP1
protein by the nonsense mutation described by Alazami et al. [55] has a more extreme consequence
on the protein than a missense SNV and therefore could account for the severity of the disease in
humans compared with our GS cases. Currently, there are no reports of NECAP1 implicated in retinal
degeneration in any species.
While NECAP1 was initially reported to be primarily expressed in brain tissue [52], it has also
been detected throughout the central nervous system in mice, including the spinal cord [55] and
retina of mice and beagle dogs [58,59]. Retinal RNAseq data generated for an unrelated project
from a PBGV dog revealed that NECAP1 is highly expressed in canine retinal tissue. Previous work
involving RP mouse models demonstrated the role of CME in retinal cells. Park et al. showed
that CME is present in the rod bipolar cell axon terminals in the mouse retina, suggesting that this
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process may be important for normal synaptic function in the mammalian retina. RP mouse models
of early onset retinal degeneration produced by a mutation in the Pde6b gene showed changes in
the postsynaptic cells of the rod and cone photoreceptors in the retina. Specifically, bipolar cells
in rod photoreceptor cells, involved in the rod neural pathway, generate ribbon synapses that are
usually formed by postnatal day 14 in mice retinas [60]. Preferential changes in endocytosis at the
rod bipolar ribbon synapses were reported in mice exhibiting rapid photoreceptor degeneration,
including abnormal synaptic ribbons in rod bipolar cells where clathrin was no longer expressed
in comparison to a control mouse retina [60]. Moreover, an example of a gene involved in CME
causing RP in humans is the receptor expression enhancing protein-6 (REEP6) gene [1,61]. REEP6
is involved in intracellular trafficking of CCVs to membrane sites, and a loss of REEP6 function
resulted in photoreceptor cell death in mouse models [61]. Studies using Drosophila as an RP disease
model highlight the significance for endocytosis of rhodopsin, a light sensitive protein which is
crucial component of the phototransduction cascade triggering vision. Endocytosis of metarhodopsin,
the active form of rhodopsin, in rhabdomeres present in Drosophila photoreceptors, is essential for
photoreceptor maintenance. Endocytosis of metarhodopsin is facilitated by the binding of arrestin
to AP-2, hence when this pathway is compromised, metarhodopsin accumulates in the rhabdomeres
and leads to the degeneration of photoreceptors [62]. Examples of rhodopsin accumulation caused
by mutations in genes involved in endolysosomal pathways [63,64] suggest reduced endocytosis in
photoreceptors lead to an accumulation of rhodopsin in photoreceptor cells, leading to photoreceptor
cell death and ultimately retinal degeneration.
Although there is no direct functional evidence supporting the involvement of NECAP1 on retinal
function, mutations discussed in endolysomal trafficking genes with similar molecular mechanisms
to NECAP1 suggest this is a provocative novel candidate gene for retinal degeneration. Studies
discussed in mice suggest that CME is essential for processes at the rod bipolar ribbon synapses
in the mammalian retina [60,61], therefore, we can venture that if the expression or function of a
gene regulating this process is disrupted, its role in maintaining rod bipolar ribbon synapses and
subsequently photoreceptor function may be compromised. We speculate that the NECAP1 glycine
to arginine substitution identified in GS dogs with PRA impacts protein function, and that potential
inactivation of the AP-2 adaptor complex could disrupt endocytosis in retinal neurons, such as
ribbon synapses in photoreceptor and bipolar cells. We hypothesize that, as a consequence of CME
disturbance in the retina, rhodopsin accumulates in the photoreceptors, leading to cell death and
retinal degeneration. Despite the addition of verifying NECAP1 expression in a normal dog retina, a
notable limitation of our study is the absence of tissue from affected animals, which prevented any
histology, gene expression or protein analysis to be undertaken. Although PRA is a blinding disease,
it rarely requires enucleation on welfare grounds and affected dogs are typically lost to follow up.
From a biological research perspective, this limits RNA analysis when novel candidate genes are
implicated. Our study presents further possibilities to explore NECAP1 involvement in canine and
human retinal degenerations.
We have shown the NECAP1 missense variant segregates with disease in the studied GS family,
as well as being detected in heterozygous state in additional breeds. Our screening cohort included
65 Miniature Schnauzers, in which no copies of the NECAP1 variant were identified. This is not
too extraordinary, as the Miniature Schnauzer and GS are recognized as distinct breeds. Additional
genotyping of Standard Schnauzers and other breeds used to develop the GS breed would be more
informative; however, sample numbers of these breeds in our DNA bank limited this scope. Due to the
presence of our candidate variant on a shared identical haplotype in additional breeds, we hypothesize
that it is due to an ancestral founder mutation event and inherited identically by descent. It is not
uncommon for deleterious mutations to be shared across breeds which appear to be unrelated, for
example the PRCD mutation has been detected in a various diverse dog breeds [11]. The German Spitz
varieties, Dachshund varieties, and GS are all breeds seemingly of German ancestry: the GS breed,
once known as the Munich Schnauzer, was developed in Germany using the Standard Schnauzer,
Genes 2019, 10, 385 13 of 17
Rottweiler, Great Dane, German Shepherd, and perhaps Bouvier De Flandres [33]. Both the Dachshund
and those Spitz varieties carrying the NECAP1 variant also originated in Germany. Shared haplotype
analysis identifies only the Standard Schnauzer, Airedale Terrier, and Black Russian Terrier as ancestors
to the GS, however, the study by Parker at al. examined haplotypes >232 kb, which are likely to detect
only more recent events. The NECAP1 haplotype we describe in the Miniature Longhaired Dachshund
is only half this size and the Giant and Medium Spitz were not examined [65]. We hypothesize that the
founding haplotype was present in a dog of German ancestry, most likely ancestors of the Dachshund
varieties, and prior to the development of these other breeds. Typically, the lengths of common shared
ancestral chromosomal segments in a population are short due to the occurrence of recombination
events over time, where the shorter haplotype in the Dachshund indicates increased recombination on
what once was a longer haplotype. The detected haplotype may have been common in the population
when the NECAP1 variant arose and, therefore, normal copies of this haplotype were also present.
We hypothesize that NECAP1 is associated with retinal degeneration and is the cause of PRA in
our GS study, despite the absence of any epileptic or neurological signs. The breed allele frequency
of 0.015 suggests that this form of PRA in the GS is rare, resulting in insufficient cases to conduct
a genome-wide association study. Due to the limited number of DNA samples from affected dogs,
we opted to directly utilize a comprehensive WGS approach to identify candidate causative variants,
with the advantage of sequencing both unaffected parents as obligate carriers to aid our analysis.
Retrospective autozygosity mapping showed the NECAP1 variant lies within a run of homozygosity
in the cases only, indicating it is identical by descent and thus providing further evidence for its
association with the disease. One limitation to this WGS approach is the detection of structural variants,
such as inversions, transposons, or large insertions/deletions which our current WGS pipeline cannot
currently identify using WGS alone, therefore, the presence of structural variation causing disease in
this study cannot be excluded. Despite this, evidence discussed suggests NECAP1 is a provocative
candidate gene for retinal degeneration.
5. Conclusions
We have identified a novel candidate variant in NECAP1 for PRA in the GS. We have demonstrated
that this variant segregates in other German breeds, suggesting it may be due to an ancestral mutation
event. To date, NECAP1 has not been associated with retinal degeneration in any species. This
study, in parallel with the known function and well-documented role of NECAP1 in clathrin-mediated
endocytosis in retinal cells, presents NECAP1 as a novel candidate gene for retinal degeneration in
dogs and other species.
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